CD8A and cervical carcinoma: Poly(I:C) dramatically increased the potent antitumour immunity induced by E749-57-EVs.Ex vivoE749-57-EVs efficiently induced anti-TC1 cervical cancer CTLs, activated proliferation of CD8+ T cells and IFN-γ synthesis.In vivoTC-1 cervical cancer modelProphylactic and therapeutic settingsE749-57-EVs vaccination (IV) resulted in activation of antitumour immune response in both treatment regimens.poly(I:C)-E749-57-EVs vaccination markedly inhibited tumour growth and improved the overall survival rate (60% of mice).